HP570 Tablets Receive Clinical Trial Approval from the U.S. FDA; Oral Molecular Glue Degrader Targeting VAV1 Advances into the Clinic
Recently, Hinova Pharmaceuticals received notification from the U.S. Food and Drug Administration (the "FDA") that the clinical trial application for its independently developed HP570 tablets, for the treatment of rheumatoid arthritis (RA), has been formally approved by the U.S. FDA.
About HP570 Tablets
HP570 tablets are an oral VAV1 molecular glue degrader independently developed by the company. VAV1 is a guanine nucleotide exchange factor (GEF) predominantly expressed in immune cells that mediates T-cell and B-cell activation, representing an important target in autoimmune diseases.
HP570 selectively degrades VAV1 with high selectivity, inhibiting aberrant immune activation, and holds therapeutic potential across a range of autoimmune diseases. VAV1 sits at an upstream hub in the T-cell receptor (TCR) and B-cell receptor (BCR) signaling pathways, and its aberrant activation is closely linked to the onset and progression of multiple autoimmune diseases. Due to challenges such as the absence of a classical small-molecule binding pocket, VAV1 has long been regarded as an "undruggable" target; molecular glue degradation technology offers a viable path for drug development against this target.
Currently, the Investigational New Drug (IND) application for this program remains under review by China's drug regulatory authority, having already received approval from the U.S. FDA, with a Phase I clinical trial to be initiated shortly.
Preclinical studies have shown that the product possesses high selectivity and potent target-degradation activity, demonstrating good efficacy across multiple autoimmune disease animal models and activity superior to that of other VAV1 degraders in human immune cells, making it a potential best-in-class oral VAV1 molecular glue degrader. The product also exhibits favorable oral absorption and bioavailability; in preliminary toxicology studies in rats and cynomolgus monkeys, it was generally well tolerated, with no clear dose-related severe toxicity signals observed.
Autoimmune diseases are a class of chronic conditions caused by aberrant activation of the immune system attacking the body's own normal tissues. It is estimated that more than 5% of the global population suffers from autoimmune diseases, with the incidence of conditions such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD), and multiple sclerosis (MS) rising year by year, imposing a heavy disease burden on patients and society.
Currently, the treatment of autoimmune diseases still relies mainly on glucocorticoids, conventional disease-modifying antirheumatic drugs (DMARDs), and biologics; yet a large number of patients remain unable to obtain effective treatment or face severe adverse reactions, reflecting substantial unmet clinical need. According to Frost & Sullivan, the global autoimmune drug market is projected to reach US$176.7 billion by 2030, indicating vast market potential.
Disclaimer:
1. This article is intended to share updates on academic frontiers and is for reference by healthcare professionals for academic purposes only. It is not for advertising purposes. Hinova Pharmaceuticals does not make any recommendation, commitment, or guarantee regarding any drug or indication.
2. If any content in this article concerns information on products not yet marketed, such products are at the research, development, or clinical trial stage and are subject to uncertainty; the final outcome shall be subject to the approval of the National Medical Products Administration.
3. Risk warning: Any forward-looking statements in this article concerning judgments about the external environment, the company's development strategy, or future plans do not constitute a substantive commitment by the company to investors. Investors are advised to invest rationally and to pay attention to investment risks.
- Hinova's Clinical Trial Application for the Combination of HP501 Sustained-release Tablets and xanthine oxidase inhibitors in the Treatment of Hyperuricemia/Gout was Accepted by NMPA
- Hinova Receives FDA Proceed Authorization for its IND Application for HP518, an Orally Bioavailable Chimeric Degrader Targeting Androgen Receptor for Prostate Cancer Treatment
- Hinova Disclosed the Preclinical Results of HP518 (Oral AR PROTAC) at the 5th Annual TPD Summit
- Hinova Announces Phase III Clinical Trial of Deutenzalutamide (HC-1119) in Chinese Patients with castration-resistant prostate cancer (mCRPC) Met Primary Endpoint
- Hinova Today Listed on the Science and Technology Innovation Board (the “STAR Market”) of the Shanghai Stock Exchange (SSE) in China, Relying on PROTAC and Deuterium Technology to Develop Innovative D


